Giant cell arteritis: An updated review of an old disease.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31291180.
- Also identified by DOI 10.3949/ccjm.86a.18103.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Giant cell arteritis is a common systemic vasculitis that affects the elderly and has a variable clinical presentation. Physicians should be aware of its different clinical phenotypes so that they can recognize it early and promptly initiate glucocorticoids, the mainstay of therapy. Clinicians should also be familiar with the toxicity of glucocorticoids and how to manage adverse effects. Tocilizumab, an interleukin 6 receptor inhibitor, is emerging as a glucocorticoid-sparing treatment, though its long-term safety and efficacy are still under study.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Giant Cell Arteritis
- Glucocorticoids